Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
This press release is being prepared.
The market announcement is already indexed, but the document has not finished syncing to our storage yet.